Skip to main content

Market Overview

Wedbush: Y-mAbs Could Attract Investor Attention As Market Volatility Grows

Wedbush: Y-mAbs Could Attract Investor Attention As Market Volatility Grows

Shares of Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) seem undervalued, given the market opportunities of the company’s core, late stage assets as well as upside potential from its label expansions and earlier-stage pipeline efforts, according to Wedbush.

The Analyst

Wedbush’s David Nierengarten initiated coverage of Y-mAbs Therapeutics with an Outperform rating and a price target of $38.

The Thesis

Markets are likely to become increasingly volatile over the next 12 months, due to macroeconomic and political factors. Against this backdrop, stocks like Y-mAbs Therapeutics, which have advanced assets as well as upside potential, should be “particularly attractive for investors,” Nierengarten said in the initiation note.

Two of the company’s lead candidates, naxitamab and radiolabeled 131I-omburtamab, have exhibited positive results in patients with neuroblastoma.

The analyst expects the Biologics License Application (BLA) filings, both of which are scheduled for the fourth quarter, to be successful and for both candidates to be approved in 2020.

Y-mAbs has label expansion opportunities in the near term, into front-line high risk and retreating neuroblastoma for both the candidates and additionally osteosarcoma for naxitamab, Nierengarten mentioned.

The company’s pipeline includes a therapeutic cancer vaccine, bispecific antibody programs and Lu177-omburtamab. Y-mAbs earlier stage efforts, particularly radiolabeled Lu177-omburtamab, “could provide significant upside as it progresses through the clinic to treat B7-H3 positive CNS/LM (central nervous system / leptomeningeal metastasis) tumors in adults,” Nierengarten wrote.

Price Action

Shares of Y-mAbs Therapeutics were up 168% to $25.91 Wednesday.

Related Links
The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering
The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO

Latest Ratings for YMAB

Mar 2021HC Wainwright & Co.MaintainsBuy
Jan 2021B of A SecuritiesDowngradesBuyNeutral
Nov 2020Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for YMAB
View the Latest Analyst Ratings


Related Articles (YMAB)

View Comments and Join the Discussion!

Posted-In: David NierengartenAnalyst Color News Health Care Price Target Initiation Analyst Ratings General

Latest Ratings

IRIXRoth CapitalMaintains9.0
AMRSRoth CapitalMaintains33.0
VORBarclaysInitiates Coverage On56.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at